Chirality in drug design

I. Lantos, V. Novack, in Chirality in Drug Design and Synthesis, C. Brown (ed.), Academic Press, New York, 1990, pp. 167-180. 

Hyneck, M. Dent, J. Hook, J. Chirality pharmacological action and drug development. In Chirality in Drug Design and Synthesis, Brown, C., Ed. Academic Press San Diego, 1990 1-28. 

Brown, C. Chirality in Drug Design and Synthesis Academic Press San Diego, 1990 243. 

Triggle, D.J. (2002) Chirality in drug design and development. In Lough, J. and Wainer, I. (eds). Chirality in Natural and Applied Science, pp. 109-138. Blackwell, Oxford. 

Brooks WH, Guida WC, Daniel KG. The significance of chirality in drug design and development. Curr. Top. Med. Chem. 2011 ll(7) 760-770. 

It should be pointed out that one is focused on properties of molecules in the absence of the receptor in contrast to the detailed focus on the complex in drug design studies. Many approaches to similarity fail to even consider chirality, a common discriminator of receptors. For a recent overview of the current status of virtual screening in lead discovery, see the review by Oprea and Matter [82]. 

Given the importance of fluorination in drug design, chiral A/-fluoro reagents were also sought after and developed. The first such reagents to be developed were the V-fluorocamphorsultams (a sultam is a cyclic sulfonamide) ... 

Chirality refers to molecules that have nonsuperimpos-able mirror images. Most chiral molecules contain one or more asymmetric carbon atoms. Chiral molecules are widespread in biological systems and are important in drug design. 

---